

# Large Data and the Opportunity to Regain Previously Lost Opportunities

– Drug Repurposing as an example

Stefan Jovinge MD PhD



LUND  
UNIVERSITY



Skåne University Hospital


# Disclosure

- Advisor to OneCell™
- Stanford University
- University of Texas South Western
- Michigan State University
- Lund University



# Growing Health Burden

Percentage of population aged 60 years or over by region, from 1980 to 2050




Data source: United Nations (2017). World Population Prospects: the 2017 Revision.




LUND  
UNIVERSITY

Health Care Cost (1970-2016)





Skåne University Hospital

# Drug Development – Losing Grounds





# Use of Electronic Medical Records in US



# Internet of Things


Sources












# Cost per Human Genome

Granularity








# Large Data – The Danger of Averaging




# Large Data – The Danger of Averaging






# Rare Diseases Are Common





# Why would this work?

- Because drugs are not “one trick ponies”
  - Even though we think of them that way.
- Additional direct effects
- Additional down stream effects
- Drugs are complex three dimensional entities



# Heart Failure


European Journal of Heart Failure 1 (1999) 401–406

www.elsevier.com/

Extended short report

## Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study

Alison F.C. Lee<sup>a,\*</sup>, Robert J. MacFadyen<sup>b</sup>, Allan D. Struthers<sup>c</sup>



The NEW ENGLAND  
JOURNAL of MEDICINE


ESTABLISHED IN 1812

APRIL 10, 2008


VOL. 358 NO. 15

Telmisartan, Ramipril, or Both in Patients at High Risk  
for Vascular Events


The ONTARGET Investigators\*




# Transcriptomics – Beyond Proteomics





# Transcriptomics – Beyond Prot



## NON-COMPETITIVE INHIBITION




## COMPETITIVE INHIBITION







# FINGER-PRINTING DRUGS




# Lamin A/C Haploinsufficient Cardiomyopathy




Healthy Allele


Disease Allele



# LMNA Haploinsufficiency Signature Definition







# LMNA Knockdown Signature Reversion





# In Vitro Validation – Transcriptomics and Function



# Drug Repurposing Principle

**Candidate Selection:** 1 week  
< \$500

**Validation:** 3  
< \$50,000

**NIH LINCS  
L1000 Dataset**


Phase I Data Release:  
~5000 genetic perturbagens  
~20000 chemical perturbagens  
~700 FDA approved compounds

Vehicle Control Z-scores

Define LMNA Signature



Score FDA Approved Drugs

LMNA<sup>wt/wt</sup>



**Sale  
price**

< \$ 50,000



**LUND**  
UNIVERSITY




**Skåne University Hospital**

# Summary

- Older population increases the need of healthcare
- The cost drug development has risen to the level where it doesn't cope with the challenges
- Big data offers opportunities not only within AI but also with detailed analyzes and the delivery of care
- One major challenge we face is to stay granular with our data as it grows

# Questions / Comments




# Acknowledgements

**SPECTRUM HEALTH**   **VAN ANDEL INSTITUTE**  
DeVos Cardiovascular Research Program / Jovinge Lab


**Stefan Jovinge MD, PhD**

- Lucas Chan PhD
- Ellen Ellis
- Emily Eugster, MA
- Joseph Faski, BS
- Jens Forsberg, PhD
- Cathy Kelty, MS
- Christy Milliron, PhD
- Jenni Schuitema, MA
- Nabin Shrestha, PhD
- Matthew Weiland, MS



**Joseph C Wu MD PhD**

- Nazish Sayed MD PhD



Eric Kort MD

